José Chang

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Weekly Epoetin Alfa Maintains Hemoglobin, Improves Quality of Life, and Reduces Transfusion in Breast Cancer Patients Receiving Chemotherapy

José Chang, Félix Couture, Scott Young et al. · Journal of Clinical Oncology · 2004 · 168 citations · Full text

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

Kathleen I. Pritchard, Janusz Rolski, Zsuzsanna Pápai et al. · Breast Cancer Research and Treatment · 2010 · 89 citations

Advanced Breast Cancer, Breast Oncology, Oncology +12

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer

Giuseppe Capri, José Chang, S.-C. Chen et al. · Annals of Oncology · 2009 · 86 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +9

The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines

George Dranitsaris, Daniel Rayson, Mark Vincent et al. · Breast Cancer Research and Treatment · 2007 · 75 citations

Predictive Model, Metastatic Breast Cancer, Breast Oncology +6